11-29-2008, 08:05 PM
|
 |
Reader
|
� |
Join Date: Apr 2006
Location: Propecia, CA
Posts: 1,838
|
|
Fish Oil vs. Hot Flashes
Quote:
Menopause. 2008 Nov 20. [Epub ahead of print]
Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.
Lucas M, Asselin G, M�rette C, Poulin MJ, Dodin S.
From the 1Saint-Fran�ois d'Assise Hospital (Centre Hospitalier Universitaire de Qu�bec); 2Department of Psychiatry, Robert Giffard Research Centre; and 3Department of Obstetrics and Gynecology, Laval University, Qu�bec, Canada.
OBJECTIVE: To compare the effects of enriched ethyl-eicosapentaenoic acid (E-EPA) omega-3 fatty acid supplementation with those of placebo on hot flashes (HFs) and quality of life among middle-aged women.
DESIGN: Women were considered for participation if they were between 40 and 55 years of age and had moderate to severe psychological distress. A total of 120 women were randomly assigned to E-EPA or placebo for 8 weeks.
Only women with HFs were included in this analysis (E-EPA, n = 45; placebo, n = 46). Outcomes were changes from baseline to week 8 postintervention regarding hot flash (HF) frequency (number of HFs per day), intensity and score (frequency x intensity), and Menopause-specific Quality of Life questionnaire scores.
RESULTS: At baseline, the average number of HFs was 2.8 per day. After 8 weeks, HF frequency and score decreased significantly in the E-EPA group compared with the placebo group. There was no difference in the change in HF intensity between groups.
Frequency of HFs declined by a mean of 1.58 per day (95% CI, -2.18 to -0.98) in the E-EPA group and by 0.50 per day (95% CI, -1.20 to 0.20) in the placebo group. The odds of being a responder among those taking E-EPA were about three times greater than among those taking placebo (odds ratio, 2.70; 95% CI, 1.03-7.03; P = 0.04).
Menopause-Specific Quality of Life scores improved significantly over time in both groups but no significant differences were noted between them.
CONCLUSIONS: Supplementation with E-EPA omega-3 fatty acid reduced HF frequency and improved the HF score relative to placebo. These results need to be confirmed by a clinical trial specifically designed to evaluate HFs in more symptomatic women.
|
Effects of ethyl-eicosapentaenoic acid omega-3 fat...[Menopause. 2008] - PubMed Result
|
Linear Mode
